Recent clinical experience with oncolytic viruses

O. G. Donnelly, F. Errington-Mais, R. Prestwich, K. Harrington, H. Pandha, R. Vile, A. A. Melcher

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

There has been interest in using viruses to treat cancer for over a century. Recent clinical efforts, driven on by significant preclinical advances, have focussed on the safety of using replication-competent viruses. Recently published clinical trials of six oncolytic viruses (adenovirus, reovirus, measles, herpes simplex, Newcastle disease virus and vaccinia) have added to the accumulating data that endorse oncolytic viruses as a safe and well tolerated treatment approach. Conclusive evidence of efficacy remains to be demonstrated, but randomised clinical trials are now underway.

Original languageEnglish (US)
Pages (from-to)1834-1841
Number of pages8
JournalCurrent Pharmaceutical Biotechnology
Volume13
Issue number9
DOIs
StatePublished - Jul 2012

Keywords

  • Adenovirus
  • Measles
  • Oncolytic virus
  • Reovirus
  • Vaccinia

ASJC Scopus subject areas

  • Biotechnology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Recent clinical experience with oncolytic viruses'. Together they form a unique fingerprint.

  • Cite this

    Donnelly, O. G., Errington-Mais, F., Prestwich, R., Harrington, K., Pandha, H., Vile, R., & Melcher, A. A. (2012). Recent clinical experience with oncolytic viruses. Current Pharmaceutical Biotechnology, 13(9), 1834-1841. https://doi.org/10.2174/138920112800958904